- Trial phase
- Phase 2/3 (registrational)
- Time to market
- If EMBRAVE3 topline results are positive, an NDA submission could follow in 2027, with potential FDA approval in 2028 given the Breakthrough Therapy and Rare Pediatric Disease designations that enable accelerated review.
- Why 4/10
- No hard dated binary catalyst (PDUFA or pivotal readout date) is scheduled for elsunersen in the next ~12 months; the EMBRAVE3 registrational topline readout was guided for 2026 but remains undated as of November 2026. The drug is also a third-priority asset behind relutrigine (PDUFA Dec 27, 2026) and ulixacaltamide (PDUFA Jan 29, 2027), which are the company's near-term value drivers.
Watch for EMBRAVE3 registrational topline results, which were expected in 2026 per the company's December 2025 guidance but have not yet been announced. Positive data would support an NDA filing; a miss or delay would push the timeline out significantly. The stock's near-term binary catalysts are relutrigine's PDUFA on December 27, 2026, and ulixacaltamide's PDUFA on January 29, 2027, which will likely dominate price action before elsunersen data emerges.
Price Chart
Executive Summary
Elsunersen (PRAX-222) is Praxis Precision Medicines' antisense oligonucleotide for SCN2A gain-of-function developmental and epileptic encephalopathy (DEE), a rare genetic epilepsy in infants. Phase 2 EMBRAVE Part A results showed a 77% sham-adjusted seizure reduction (p=0.015) with a favorable safety profile, earning FDA Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations. The registrational EMBRAVE3 study was converted to a single-arm design with FDA agreement in December 2025, with topline results originally guided for 2026 but not yet reported as of November 2026. Elsunersen is a promising but later-stage pipeline asset behind Praxis' two lead programs (relutrigine and ulixacaltamide) that have PDUFA dates in late 2026 and early 2027.
How It Works
Elsunersen is an antisense oligonucleotide, a type of synthetic genetic medicine designed to reduce the production of the SCN2A protein. In patients with SCN2A gain-of-function mutations, the sodium channel protein is overactive, causing severe, hard-to-treat seizures starting in infancy. By lowering SCN2A gene expression, elsunersen aims to correct the underlying genetic imbalance and reduce seizure frequency.
Trial Status
EMBRAVE Part A (Phase 2, n=9) completed with positive topline results announced April 2026. EMBRAVE3, the single-arm registrational study, is ongoing with enrollment accelerating as of December 2025; topline results were expected in 2026 but have not yet been reported.
The Two-Sided Case
Upcoming Catalysts
- EMBRAVE3 registrational topline results (expected 2026, no specific date announced)
- Potential NDA submission following positive EMBRAVE3 data
- FDA Rare Pediatric Disease priority review voucher eligibility upon NDA acceptance
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Praxis Precision Medicines, Inc. 8-K PRAX ·Originating report